Oculis reports Phase 2 biomarker data supporting Privosegtor’s neuroprotective potential in optic neuritis

PUBT · 2d ago
Oculis reports Phase 2 biomarker data supporting Privosegtor’s neuroprotective potential in optic neuritis
  • Oculis reported new Phase 2 ACUITY biomarker results supporting privosegtor's potential to protect nerves in patients with optic neuritis.
  • Treated patients showed smaller increases in blood markers associated with nerve damage and inflammatory responses than those receiving placebo.
  • The findings reinforce previously reported improvements in visual function and preservation of retinal structure.
  • Results were presented at the ACTRIMS-ECTRIMS joint meeting, MSToronto 2026.
  • Privosegtor remains investigational in the PIONEER registration program; Oculis also plans a clinical trial application targeting acute multiple sclerosis relapses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220200OMX_____CNEWS_IS_GNW1001279267_is) on October 22, 2026, and is solely responsible for the information contained therein.